Boston, MA 06\/10\/2014 (wallstreetpr) \u2013\u00a0Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)<\/b>\u2019s shares pumped up on Monday powered by upbeat investments, as speculations are rife that ACHN can emerge as the next big Hepatitis-C takeout target.<\/p>\n
IDIX Buyout: A Timely Move<\/b><\/p>\n
Merck & Co., Inc.(NYSE:MRK),<\/b> a globally renowned healthcare company took over the reigns of Idenix Pharmaceuticals Inc (NASDAQ:IDIX)<\/b> on Monday at a whopping $3.85 billion deal. Soon after this big news made the headlines on Monday, the share price plummeted up nearly 229% by the day\u2019s close.<\/p>\n
MRK unveiled a planned strategic acquisition of IDIX at a juncture wherein the latter has four exquisite Hepatitis C treatments under its disposition, among with two are currently in Phase2-Trials, another in Phase1-Trials and the fourth one is merely in its preclinical trials.<\/p>\n
IDIX has also filed petitions and sued Gilead Sciences, Inc. (NASDAQ:GILD)<\/b>, claiming that the latter’s Hepatitis-C drug \u2013 Sovaldi holistically infringes upon IDIX’s previous patents. Thus, it is implied that MRK’s move was a cautious and tactical bid to buy IDIX at such a crucial juncture; MRK might expect gobbling up maximal profits, lest certain uncalled for disaster doldrums are inflicted upon it. Incidentally, GILD’s shares have tumbled further as investors speculate that the MRK-IDIX deal bears testimony to GILD’s fallibility over the patent-issues.<\/p>\n
All Eyes On ACHN<\/b><\/p>\n
The IDIX acquisition deal tantalized ACHN investors largely because all and sundry are aware of the contention that MRK had to face during its acquisition process, with a major research based pharma company, AbbVie Inc (NYSE:ABBV)<\/b> and another prime name in the healthcare industry \u2013 Johnson & Johnson (NYSE:JNJ)<\/b>.<\/p>\n
Traders quite rightly anticipate that ACHN shall have many bidders in the days to come, as major pharma or healthcare companies won\u2019t allow their rival MRK build its own Hepatitis-C drugs\u2019 user-base, without any competition.<\/p>\n
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) possesses a profound Hepatitis-C drug pipeline, just like IDIX. The major drugs in the pipeline are a fast-track NS5A-Inhibitor drug \u2013 ACH-3102, another NS3\/4-Inhibitor drug \u2013 ACH-2684 and an NS5B-Inhibitor \u2013 ACH-3422. ACH-3422 is perhaps the most valuable \u2018Nuc’ available with ACHN, that shall bolster the Hepatitis-C treatment.<\/p>\n
The GILD Model<\/b><\/p>\n
Gilead Sciences, Inc. (NASDAQ:GILD) had announced that the Q1 sales of its antiviral products soared up 119% year-over-year, powered by Sovaldi\u2019s gains of $2,274,349! Enhanced profitability and market gains by selling Hepatitis C drugs have evolved as the basis for MRK\u2019s IDIX acquisition, and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)\u2019s sell-out anticipations!<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 06\/10\/2014 (wallstreetpr) \u2013\u00a0Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)\u2019s shares pumped up on Monday powered by upbeat investments, as speculations are rife that ACHN can emerge […]<\/p>\n","protected":false},"author":3,"featured_media":25320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1593,2990,1978,1945,1744,1683,2991,1522,1946,1592,995,1123],"stock_ticker":[],"class_list":["post-25313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc-nyseabbv","tag-achillion-pharmaceuticals-inc-nasdaqachn","tag-gilead-sciences-inc-nasdaqgild","tag-idenix-pharmaceuticals-inc-nasdaqidix","tag-johnson-johnson-nysejnj","tag-merck-co-inc-nysemrk","tag-nasdaqachn","tag-nasdaqgild","tag-nasdaqidix","tag-nyseabbv","tag-nysejnj","tag-nysemrk","entry"],"acf":[],"yoast_head":"\n